Imunon reports positive Phase 2 MRD data for IMNN-001 in frontline ovarian cancer
IMNN•Phase 2 MRD results support ongoing Phase 3 trial
Imunon reported preliminary Phase 2 MRD data for IMNN-001 in newly diagnosed advanced ovarian cancer, supporting its ongoing Phase 3 OVATION 3 trial.
- Second-look laparoscopy showed lower MRD-positive rates with IMNN-001 vs. control: 44% vs. 67%.
- ctDNA clearance was 87.5% vs. 62.5%.
- Safety remained favorable, with no cytokine release syndrome, systemic toxicities, or serious immune-related adverse events reported to date.
